Aurinia Pharmaceuticals (AUPH) Current Assets (2016 - 2026)

Aurinia Pharmaceuticals has reported Current Assets for 11 years, with the latest figure at $480.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 18.36% year-over-year to $480.2 million; the trailing twelve-month figure through Mar 2026 stood at $480.2 million (up 18.36% YoY), and the FY2025 full-year result was $492.0 million, up 10.16% from the prior year.
• Current Assets for Q1 2026 stood at $480.2 million, down from $492.0 million in the prior quarter.
• The five-year high for Current Assets was $492.0 million in Q4 2025, with the low at $398.2 million in Q1 2024.
• Historically, Current Assets has averaged $437.9 million across 5 years, with a median of $438.7 million in 2025.
• The largest YoY upside for Current Assets was 39.63% in 2022 against a maximum downside of 13.79% in 2022.
• Aurinia Pharmaceuticals' Current Assets stood at $442.5 million in 2022, then slipped by 4.01% to $424.8 million in 2023, then advanced by 5.13% to $446.6 million in 2024, then climbed by 10.16% to $492.0 million in 2025, then dropped by 2.38% to $480.2 million in 2026.
• The last three Current Assets figures came in at $480.2 million (Q1 2026), $492.0 million (Q4 2025), and $438.7 million (Q3 2025), per Business Quant data.